- Records
- 19
- Recruiting
- 11
- Recruiting sites
- 613
- Countries
- 18
ClinicalTrials.gov registry snapshot / 2026-07-24Peptide trials,
Peptide trials,
without the maze.
Search every official registry record matched to 13 tracked peptide and next-generation weight-loss programs. Find current status, phase, enrollment, countries, US states, recruiting cities, postal areas, completion timing, and the direct NCT source.
268unique NCT records
13named programs
53countries represented
1,840recruiting cities
11registry result modules
Recruiting footprint by program
Study status is not drug rank.
Bar length shows registry-listed sites individually marked Recruiting. Larger programs can create larger counts. This does not compare efficacy, safety, approval odds, sponsor quality, or enrollment availability.
- Records
- 52
- Recruiting
- 10
- Recruiting sites
- 170
- Countries
- 7
- Records
- 37
- Recruiting
- 10
- Recruiting sites
- 73
- Countries
- 3
- Records
- 24
- Recruiting
- 10
- Recruiting sites
- 935
- Countries
- 28
- Records
- 27
- Recruiting
- 6
- Recruiting sites
- 1,581
- Countries
- 36
- Records
- 30
- Recruiting
- 5
- Recruiting sites
- 155
- Countries
- 6
- Records
- 8
- Recruiting
- 4
- Recruiting sites
- 339
- Countries
- 23
- Records
- 31
- Recruiting
- 3
- Recruiting sites
- 774
- Countries
- 34
- Records
- 15
- Recruiting
- 3
- Recruiting sites
- 3
- Countries
- 1
- Records
- 34
- Recruiting
- 2
- Recruiting sites
- 450
- Countries
- 27
- Records
- 9
- Recruiting
- 2
- Recruiting sites
- 4
- Countries
- 3
- Records
- 9
- Recruiting
- 1
- Recruiting sites
- 8
- Countries
- 1
- Records
- 5
- Recruiting
- 0
- Recruiting sites
- 0
- Countries
- 0
Official registry finder
Filter the exact records.
Search names, former codes, NCT IDs, sponsors, interventions, conditions, cities, and postal codes. Filtered URLs are shareable but intentionally excluded from search indexing so this page remains the canonical source.
37matching registry records
Snapshot timestampJuly 24, 2026 at 9:00 AM UTC
| Program and record | Status | Phase and enrollment | Locations | Primary completion | Registry update | Source |
|---|---|---|---|---|---|---|
| A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or OverweightNCT06143956 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 21,481 estimated | 47 recruiting54 listed / 2 countries | Sep 2027estimated | Jul 20, 2026ClinicalTrials.gov | Open NCT06143956 ↗ |
| Efficacy of Mazdutide for Treating PCOSNCT06519656 / Shanghai Zhongshan Hospital | RecruitingVerified 2024-10 | Phase 1 / Phase 250 estimated | 1 recruiting1 listed / 1 countries | Dec 31, 2025estimated | Oct 24, 2024ClinicalTrials.gov | Open NCT06519656 ↗ |
| A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With ObesityNCT06862908 / Innovent Biologics (Suzhou) Co. Ltd. | RecruitingVerified 2025-07 | Phase 2141 estimated | 1 recruiting1 listed / 1 countries | Sep 24, 2026estimated | Jul 11, 2025ClinicalTrials.gov | Open NCT06862908 ↗ |
| A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2NCT06931028 / Innovent Biologics (Suzhou) Co. Ltd. | RecruitingVerified 2025-06 | Phase 3260 estimated | 1 recruiting1 listed / 1 countries | May 7, 2027estimated | Jun 29, 2025ClinicalTrials.gov | Open NCT06931028 ↗ |
| A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)NCT06937749 / Innovent Biologics (Suzhou) Co. Ltd. | RecruitingVerified 2025-11 | Phase 2165 estimated | 1 recruiting1 listed / 1 countries | Apr 30, 2026estimated | Nov 20, 2025ClinicalTrials.gov | Open NCT06937749 ↗ |
| GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)NCT07083154 / The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | RecruitingVerified 2026-03 | Phase 3420 estimated | 6 recruiting8 listed / 1 countries | Aug 1, 2029estimated | Mar 5, 2026ClinicalTrials.gov | Open NCT07083154 ↗ |
| A Study of IBI362 in Chinese Adolescents With Obesity or OverweightNCT07255209 / Innovent Biologics (Suzhou) Co. Ltd. | RecruitingVerified 2026-01 | Phase 3180 estimated | 1 recruiting1 listed / 1 countries | Oct 31, 2027estimated | Jan 8, 2026ClinicalTrials.gov | Open NCT07255209 ↗ |
| Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/ObesityNCT07469800 / Innovent Biologics (Suzhou) Co. Ltd. | RecruitingVerified 2026-05 | Phase 3336 estimated | 1 recruiting1 listed / 1 countries | Aug 1, 2026estimated | May 27, 2026ClinicalTrials.gov | Open NCT07469800 ↗ |
| ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight ManagementNCT07517042 / Shanghai Zhongshan Hospital | RecruitingVerified 2025-12 | Not applicable420 estimated | 13 recruiting13 listed / 1 countries | Dec 2028estimated | Apr 8, 2026ClinicalTrials.gov | Open NCT07517042 ↗ |
| GLP-1 Therapy After Bariatric Surgery in Chinese Patients With ObesityNCT07633639 / China-Japan Friendship Hospital | RecruitingVerified 2026-05 | Not applicable200 estimated | 1 recruiting1 listed / 1 countries | May 1, 2028estimated | Jun 8, 2026ClinicalTrials.gov | Open NCT07633639 ↗ |
| Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe ObesityNCT07135141 / SMART / Beijing Friendship Hospital | Not yet recruitingVerified 2025-08 | Not applicable256 estimated | 0 recruiting14 listed / 1 countries | Sep 30, 2027estimated | Aug 21, 2025ClinicalTrials.gov | Open NCT07135141 ↗ |
| A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) InhibitorNCT07417306 / Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Not yet recruitingVerified 2026-02 | Phase 3912 estimated | 0 recruiting1 listed / 1 countries | Aug 30, 2027estimated | Feb 18, 2026ClinicalTrials.gov | Open NCT07417306 ↗ |
| Mazdutide for Adults With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial (DREAM-PRE)NCT07654062 / DREAM-PRE / Shandong Provincial Hospital | Not yet recruitingVerified 2026-06 | Phase 4150 estimated | 0 recruiting1 listed / 1 countries | Jun 2028estimated | Jun 17, 2026ClinicalTrials.gov | Open NCT07654062 ↗ |
| Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or ObesityNCT07657676 / China National Center for Cardiovascular Diseases | Not yet recruitingVerified 2026-06 | Phase 4116 estimated | 0 recruiting1 listed / 1 countries | Oct 31, 2027estimated | Jun 18, 2026ClinicalTrials.gov | Open NCT07657676 ↗ |
| Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With SemaglutideNCT07713992 / Tianjin Medical University | Not yet recruitingVerified 2026-07 | Not applicable72 estimated | 0 recruiting0 listed / 0 countries | Dec 31, 2027estimated | Jul 20, 2026ClinicalTrials.gov | Open NCT07713992 ↗ |
| Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)NCT07718126 / PRIME / West China Hospital | Not yet recruitingVerified 2026-07 | Phase 2 / Phase 360 estimated | 0 recruiting3 listed / 1 countries | Aug 31, 2028estimated | Jul 21, 2026ClinicalTrials.gov | Open NCT07718126 ↗ |
| A Study of IBI362 9 mg in Chinese Adults With ObesityNCT06164873 / Innovent Biologics (Suzhou) Co. Ltd. | Active, not recruitingVerified 2024-08 | Phase 3462 actual | 0 recruiting1 listed / 1 countries | Jun 27, 2025estimated | Aug 27, 2024ClinicalTrials.gov | Open NCT06164873 ↗ |
| A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）NCT06884293 / Innovent Biologics (Suzhou) Co. Ltd. | Active, not recruitingVerified 2026-05 | Phase 3479 actual | 0 recruiting1 listed / 1 countries | Dec 31, 2026estimated | May 12, 2026ClinicalTrials.gov | Open NCT06884293 ↗ |
| Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe ObesityNCT07000955 / Innovent Biologics (Suzhou) Co. Ltd. | Active, not recruitingVerified 2025-12 | Phase 1 / Phase 298 actual | 0 recruiting1 listed / 1 countries | Sep 30, 2026estimated | Dec 15, 2025ClinicalTrials.gov | Open NCT07000955 ↗ |
| A Study of LY3305677 in Healthy ParticipantsNCT02972645 / Eli Lilly and Company | CompletedVerified 2017-07 | Phase 166 actual | 0 recruiting1 listed / 1 countries | Jul 14, 2017actual | Jul 24, 2017ClinicalTrials.gov | Open NCT02972645 ↗ |
| A Study of Multiple Doses of LY3305677 in Healthy ParticipantsNCT03325387 / Eli Lilly and Company | CompletedVerified 2018-08 | Phase 156 actual | 0 recruiting1 listed / 1 countries | Aug 3, 2018actual | Aug 16, 2018ClinicalTrials.gov | Open NCT03325387 ↗ |
| A Study of LY3305677 in Participants With Type 2 DiabetesNCT03928379 / Eli Lilly and Company | CompletedVerified 2021-07 | Phase 124 actual | 0 recruiting1 listed / 1 countries | Jul 8, 2021actual | Jul 19, 2021ClinicalTrials.gov | Open NCT03928379 ↗ |
| Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity SubjectsNCT04440345 / Innovent Biologics (Suzhou) Co. Ltd. | CompletedVerified 2023-11 | Phase 1 / Phase 260 actual | 0 recruiting1 listed / 1 countries | Jun 16, 2021actual | Nov 28, 2023ClinicalTrials.gov | Open NCT04440345 ↗ |
| Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DMNCT04466904 / Innovent Biologics (Suzhou) Co. Ltd. | CompletedVerified 2021-07 | Phase 1 / Phase 242 actual | 0 recruiting1 listed / 1 countries | May 28, 2021actual | Jul 23, 2021ClinicalTrials.gov | Open NCT04466904 ↗ |
| Clinical Study of IBI362 in Healthy Chinese Male SubjectsNCT04773977 / Innovent Biologics (Suzhou) Co. Ltd. | CompletedVerified 2021-03 | Phase 124 actual | 0 recruiting1 listed / 1 countries | Mar 9, 2021actual | Jul 8, 2021ClinicalTrials.gov | Open NCT04773977 ↗ |
| A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese SubjectsNCT04904913 / Innovent Biologics (Suzhou) Co. Ltd. | CompletedVerified 2025-11 | Phase 2328 actual | 0 recruiting1 listed / 1 countries | Mar 29, 2023actual | Nov 17, 2025ClinicalTrials.gov | Open NCT04904913 ↗ |
| A Study of IBI362 in Chinese Patients With Type 2 DiabetesNCT04965506 / Innovent Biologics (Suzhou) Co. Ltd. | CompletedVerified 2023-12 | Phase 2252 actual | 0 recruiting1 listed / 1 countries | Apr 28, 2022actual | Dec 27, 2023ClinicalTrials.gov | Open NCT04965506 ↗ |
| A Study of IBI362 in Participants With Type 2 DiabetesNCT05606913 / Innovent Biologics (Suzhou) Co. Ltd. | CompletedVerified 2024-08 | Phase 3731 actual | 0 recruiting1 listed / 1 countries | Jan 26, 2024actual | Aug 23, 2024ClinicalTrials.gov | Open NCT05606913 ↗ |
| A Study of IBI362 in Participants With Obesity or OverweightNCT05607680 / Innovent Biologics (Suzhou) Co. Ltd. | CompletedVerified 2024-11 | Phase 3610 actual | 0 recruiting23 listed / 1 countries | Aug 21, 2023actual | Nov 12, 2024ClinicalTrials.gov | Open NCT05607680 ↗ |
| A Study of LY3305677 in Participants With Obesity Or OverweightNCT05623839 / Eli Lilly and Company | CompletedVerified 2023-07 | Phase 132 actual | 0 recruiting3 listed / 1 countries | Jun 27, 2023actual | Jul 5, 2023ClinicalTrials.gov | Open NCT05623839 ↗ |
| A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and ExerciseNCT05628311 / Innovent Biologics (Suzhou) Co. Ltd. | CompletedVerified 2024-08 | Phase 3319 actual | 0 recruiting1 listed / 1 countries | Oct 25, 2023actual | Aug 20, 2024ClinicalTrials.gov | Open NCT05628311 ↗ |
| Pharmacokinetics of IBI362 in Subjects With and Without Renal ImpairmentNCT05793450 / Innovent Biologics (Suzhou) Co. Ltd. | CompletedVerified 2024-02 | Phase 120 actual | 0 recruiting1 listed / 1 countries | Sep 18, 2023actual | Feb 20, 2024ClinicalTrials.gov | Open NCT05793450 ↗ |
| A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese SubjectsNCT05815680 / Innovent Biologics (Suzhou) Co. Ltd. | CompletedVerified 2023-11 | Phase 148 actual | 0 recruiting1 listed / 1 countries | Aug 18, 2023actual | Nov 14, 2023ClinicalTrials.gov | Open NCT05815680 ↗ |
| A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or OverweightNCT06124807 / Eli Lilly and Company | CompletedVerified 2026-03Registry results posted | Phase 2179 actual | 0 recruiting29 listed / 1 countries | Jan 22, 2025actual | Apr 21, 2026ClinicalTrials.gov | Open NCT06124807 ↗ |
| A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and ObesityNCT06184568 / Innovent Biologics (Suzhou) Co. Ltd. | CompletedVerified 2026-06 | Phase 3349 actual | 0 recruiting1 listed / 1 countries | Sep 17, 2025actual | Jun 11, 2026ClinicalTrials.gov | Open NCT06184568 ↗ |
| This is a Study to Evaluate the Pharmacokinetics and Safety of IBI362 in Chinese Adolescents With ObesityNCT06536023 / Innovent Biologics (Suzhou) Co. Ltd. | CompletedVerified 2025-09 | Phase 136 actual | 0 recruiting1 listed / 1 countries | Jul 22, 2025actual | Sep 12, 2025ClinicalTrials.gov | Open NCT06536023 ↗ |
| A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use DisorderNCT06817356 / Eli Lilly and Company | CompletedVerified 2026-07 | Phase 2308 actual | 0 recruiting25 listed / 1 countries | Mar 19, 2026actual | Jul 16, 2026ClinicalTrials.gov | Open NCT06817356 ↗ |
Recruiting location footprint
Country and US state routes.
Counts are site observations across registry records, not unique facilities. The same research center can appear in multiple studies. Open the exact NCT record before treating a location as current.
Clinical trial finder FAQ
Status, location, and enrollment are different fields.
These answers prevent the most common registry-search errors before a reader follows an official source.
Are any Retatrutide clinical trials recruiting?
Yes. This 2026-07-24 snapshot contains 2 Retatrutide registry records with an overall Recruiting status and 450 listed sites individually marked Recruiting. Overall status does not mean every site is open, and neither status establishes eligibility or enrollment. Open the exact NCT record and verify the individual location before contacting a study team.
How do I find a peptide clinical trial near me?
Enter a city or postal code, optionally add a country or US state, and then open the exact ClinicalTrials.gov record. This finder retains location rows individually marked Recruiting but omits facility and personal contact fields. Confirm current recruitment, eligibility, official contact route, and travel requirements on the registry. Peptide Local does not enroll participants.
Does Recruiting mean I can join the trial?
No. Recruiting is a registry status, not an eligibility decision or appointment. A study can be recruiting overall while some listed locations are not yet recruiting, active but closed, completed, suspended, or missing a current site status. The study team applies the protocol's eligibility and consent process.
Are the drugs in this clinical trial finder FDA approved?
A ClinicalTrials.gov record is not FDA approval. The finder covers investigational programs and can also include studies involving components or comparators with separate regulatory histories. Approval must be verified on the exact FDA label or regulator record, not inferred from a phase, sponsor, trial result, or recruiting status.
Why do only some registry records show posted results?
11 of 268 records in this snapshot expose a ClinicalTrials.gov results module. A record without posted registry results can still have a publication or sponsor announcement elsewhere, while a posted module still requires careful interpretation. Results availability is not a quality rank.
How current is the peptide clinical trial data?
The registry data timestamp is July 24, 2026 at 9:00 AM UTC. The refresh workflow searches exact intervention names and aliases, deduplicates by NCT ID, preserves multi-program studies, and stores overall and individual-site status separately. Registry fields can change after that timestamp, so the direct source remains authoritative for enrollment decisions.
Evidence boundary
A registry finder, not an enrollment service.
A dated transformation of ClinicalTrials.gov intervention-search records for thirteen named Peptide Local pipeline programs. Study sponsors or investigators submit and maintain registry records. Overall status, individual-site status, enrollment, locations, completion dates, and results availability can change. Recruiting status does not establish eligibility, enrollment, treatment access, regulatory approval, routine availability, or a favorable benefit-risk conclusion.
Peptide Local omits personal contact details and does not screen participants, recommend a protocol, interpret eligibility, arrange treatment, or authenticate commercial products that reuse an investigational program's name.
Read the official API documentation ↗Understand evidence categories →